BUSINESS INSIGHTS : The latest news, analysis, and trends about protection and care

Aug 22, 2019,  by Allianz Partners Business Insights

Chronolife develops IA and a smart T-shirt for monitoring patients

Google, Apple, Facebook, and Amazon are taking a real interest in the health forecasting device PREDIGMA, developed by the French startup Chronolife. A smart T-shirt equipped with ten sensors that pick up and monitor the wearer´s vital signs, the system uses an algorithm to detect areas of concern, predict potential problems and send alerts.

Photo credits: Chronolife

French startup Chronolife has developed a smart T-shirt designed to collate, analyse and monitor various types of physiological data on the wearer. Going by the name of PREDIGMA, the smart garment is linked to a mobile app and a dedicated website, as reported by the website ObjetConnecté. The medical device makes use of artificial intelligence developed by the company, which started out in 2015.

Ten sensors for monitoring vital signs

The T-shirt boasts an algorithm called HOTS, which is designed to predict health problems thanks to information collated by ten sensors fitted in the garment and which monitor skin temperature, heart rate, pulmonary impedances with the potential to cause an oedema, and chest and abdominal breathing. The system is also capable of detecting if the user falls and can monitor their physical activity.

Using a Bluetooth connection, the T-shirt sends this information to the website or app, at which point HOTS springs into action, reviewing the date and, if necessary, making forecasts as to the likelihood of problems arising. According to Chronolife CEO Laurent VandeBrouck, the AI can predict decompensated heart failure, chronic obstructive pulmonary disease (COPD), epilepsy and sleep apnea.

Forecasting capability

Inspired by the way in which the brain operates, the neuromorphic algorithm is programmed to forecast changes in the wearer’s health and send alerts to health professionals in the event of any worrying developments. Chronolife is due to undertake a major clinical study to assess the efficiency of HOTS and PREDIGMA in detecting decompensated heart failure at an early stage.

These tests will be carried out on more than 500 patients with a history of cardiovascular events, explained VandeBrouck. In the weeks after such events, however, there is a strong probability of the patient suffering another such episode.

Significant investments

A budget of between €2m and $3m has been set aside for this stage of the study, with €4m having already been spent on launching PREDIGMA. VandeBrouck said that investment is vital to the future of the device because “we have to go through clinical phases with each illness to obtain certification and a return on the solutions”.

The investment is worthwhile, with the giants of high-tech already expressing an interest in the algorithm. “They feel HOTS can work on their own wearables and smartphones,” added VandeBrouck.

Allianz Partners

Contact
Linked Topics
About Allianz Partners Business Insights